51
Views
0
CrossRef citations to date
0
Altmetric
Review

Hip Protectors for Preventing Hip Fractures Among Elderly Adults

&
Pages 509-517 | Published online: 21 Jul 2009
 

Abstract

Prevention of fractures in the elderly consists of prevention and treatment of osteoporosis, prevention of falling and prevention of fractures using injury-site protection. Since the majority of hip fractures in elderly people are caused by a sideways fall with direct impact on the greater trochanter of the proximal femur, one option to prevent the fracture is a biomechanically effective external hip protector. The biomechanical test results of an energy-shunting and energy-absorbing hip protector have demonstrated that this type of hip protector can provide an effective impact force attenuation in typical falling conditions of older adults by reducing the initial force down to the seventh part. Recent meta-analyses and systematic reviews combining findings of all different types of hip protectors suggest that in care homes and institutions with high rates of hip fracture, the use of hip protectors might help to reduce the risk of fracture to 20–60%, but there is no evidence of a public health level benefit from hip protectors for lower-risk (usually home-dwelling) elderly people.

Financial & competing interests disclosure

This research was supported in part by the Competitive Research Funding of the Pirkanmaa Hospital District, Tampere University Hospital, Tampere, Finland, Ministry of Health and Ministry of Education, Helsinki, Finland. The authors have received grant funding, lecturing fees, or consulting fees from Aventis, MSD, Novartis, Pfizer, Respecta and Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This research was supported in part by the Competitive Research Funding of the Pirkanmaa Hospital District, Tampere University Hospital, Tampere, Finland, Ministry of Health and Ministry of Education, Helsinki, Finland. The authors have received grant funding, lecturing fees, or consulting fees from Aventis, MSD, Novartis, Pfizer, Respecta and Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Log in via your institution

Log in to Taylor & Francis Online

There are no offers available at the current time.

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.